Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chest.2020.04.024 http://scihub22266oqcxt.onion/10.1016/j.chest.2020.04.024 32343968!7195070!32343968     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Chest 2020 ; 158 (1): e15-e19 Nephropedia Template TP {{tp|p=32343968|t=2020. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report |pdf=|usr=}}{{32343968}} gab.com Text Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report JO: Chest http://www.kidney.de/pget.php?&tw=1&pmid=32343968 #FOAvip Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 4.1 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process. Twit Text FOAVip Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report ????Chest http://www.kidney.de/pget.php?&tw=1&pmid=32343968 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32343968 #FOAvip English Wikipedia <ref>{{Cite pmid|32343968}}</ref> Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report #MMPMID32343968 Radbel J; Narayanan N; Bhatt PJ Chest 2020[Jul]; 158 (1): e15-e19 PMID32343968show ga Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 4.1 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process. |*Coronavirus Infections/complications/diagnosis/physiopathology/therapy[MESH] |*Cytokine Release Syndrome/blood/therapy/virology[MESH] |*Lymphohistiocytosis, Hemophagocytic/blood/therapy/virology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/complications/diagnosis/etiology/physiopathology/therapy[MESH] |Adult[MESH] |Aged[MESH] |Anti-Infective Agents/administration & dosage[MESH] |Anti-Inflammatory Agents/administration & dosage[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |Azithromycin/administration & dosage[MESH] |Betacoronavirus/isolation & purification[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19[MESH] |Clinical Deterioration[MESH] |Fatal Outcome[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/administration & dosage[MESH] |Hypoxia/etiology/therapy[MESH] |Male[MESH] |Myocarditis/therapy/virology[MESH] |Respiration, Artificial/methods[MESH] |SARS-CoV-2[MESH]Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A C(epmc).pdf DeepDyve Pubget Overpricing